Tofen

Tofen
The information provided in of Tofen
is based on data of another medicine with exactly the same composition as the Tofen .
. Be careful and be sure to specify the information on the section in the instructions to the drug Tofen directly from the package or from the pharmacist at the pharmacy.

Qualitative and quantitative composition
The information provided in Qualitative and quantitative composition of Tofen
is based on data of another medicine with exactly the same composition as the Tofen .
. Be careful and be sure to specify the information on the section Qualitative and quantitative composition in the instructions to the drug Tofen directly from the package or from the pharmacist at the pharmacy.

The information provided in Therapeutic indications of Tofen
is based on data of another medicine with exactly the same composition as the Tofen .
. Be careful and be sure to specify the information on the section Therapeutic indications in the instructions to the drug Tofen directly from the package or from the pharmacist at the pharmacy.

Capsule, hard; Eye drops, solution; Syrup
Ophthalmic solution; Solution-drops
Dosage (Posology) and method of administration
The information provided in Dosage (Posology) and method of administration of Tofen
is based on data of another medicine with exactly the same composition as the Tofen .
. Be careful and be sure to specify the information on the section Dosage (Posology) and method of administration in the instructions to the drug Tofen directly from the package or from the pharmacist at the pharmacy.

The information provided in Contraindications of Tofen
is based on data of another medicine with exactly the same composition as the Tofen .
. Be careful and be sure to specify the information on the section Contraindications in the instructions to the drug Tofen directly from the package or from the pharmacist at the pharmacy.

Ophthalmic solution; Solution-drops
Special warnings and precautions for use
The information provided in Special warnings and precautions for use of Tofen
is based on data of another medicine with exactly the same composition as the Tofen .
. Be careful and be sure to specify the information on the section Special warnings and precautions for use in the instructions to the drug Tofen directly from the package or from the pharmacist at the pharmacy.

Effects on ability to drive and use machines
The information provided in Effects on ability to drive and use machines of Tofen
is based on data of another medicine with exactly the same composition as the Tofen .
. Be careful and be sure to specify the information on the section Effects on ability to drive and use machines in the instructions to the drug Tofen directly from the package or from the pharmacist at the pharmacy.

The information provided in Undesirable effects of Tofen
is based on data of another medicine with exactly the same composition as the Tofen .
. Be careful and be sure to specify the information on the section Undesirable effects in the instructions to the drug Tofen directly from the package or from the pharmacist at the pharmacy.

The information provided in Overdose of Tofen
is based on data of another medicine with exactly the same composition as the Tofen .
. Be careful and be sure to specify the information on the section Overdose in the instructions to the drug Tofen directly from the package or from the pharmacist at the pharmacy.

The information provided in Pharmacodynamic properties of Tofen
is based on data of another medicine with exactly the same composition as the Tofen .
. Be careful and be sure to specify the information on the section Pharmacodynamic properties in the instructions to the drug Tofen directly from the package or from the pharmacist at the pharmacy.

The information provided in Pharmacokinetic properties of Tofen
is based on data of another medicine with exactly the same composition as the Tofen .
. Be careful and be sure to specify the information on the section Pharmacokinetic properties in the instructions to the drug Tofen directly from the package or from the pharmacist at the pharmacy.

The information provided in Pharmacotherapeutic group of Tofen
is based on data of another medicine with exactly the same composition as the Tofen .
. Be careful and be sure to specify the information on the section Pharmacotherapeutic group in the instructions to the drug Tofen directly from the package or from the pharmacist at the pharmacy.

Ophthalmologicals, other antiallergics
The information provided in Preclinical safety data of Tofen
is based on data of another medicine with exactly the same composition as the Tofen .
. Be careful and be sure to specify the information on the section Preclinical safety data in the instructions to the drug Tofen directly from the package or from the pharmacist at the pharmacy.

The information provided in Incompatibilities of Tofen
is based on data of another medicine with exactly the same composition as the Tofen .
. Be careful and be sure to specify the information on the section Incompatibilities in the instructions to the drug Tofen directly from the package or from the pharmacist at the pharmacy.

Special precautions for disposal and other handling
The information provided in Special precautions for disposal and other handling of Tofen
is based on data of another medicine with exactly the same composition as the Tofen .
. Be careful and be sure to specify the information on the section Special precautions for disposal and other handling in the instructions to the drug Tofen directly from the package or from the pharmacist at the pharmacy.

Medically reviewed by Kovalenko Svetlana Olegovna, PharmD. Last updated on 2020-03-24
Symptomatic treatment of seasonal allergic conjunctivitis.
Tofen® (ketotifen fumarate ophthalmic solution) is indicated for the temporary prevention of itching of the eye due to allergic conjunctivitis.
ZADITOR® (ketotifen fumarate ophthalmic solution) is indicated for the temporary prevention of itching of the eye due to allergic conjunctivitis.
Adults and children 3 years of age and older: Put 1 drop in the affected eye(s) twice daily, every 8-12 hours, no more than twice per day.
Children under 3 years of age: Consult a doctor.
Tofen® (ketotifen fumarate) is contraindicated in persons with a known hypersensitivity to any component of this product.
ZADITOR® (ketotifen fumarate) is contraindicated in persons with a known hypersensitivity to any component of this product.
For topical ophthalmic use only. Not for injection or oral use.
Carcinogenesis, Mutagenesis, Impairment of Fertility
Ketotifen fumarate was determined to be non-mutagenic in a battery of in vitro and in vivo mutagenicity assays including: Ames test, in vitro chromosomal aberration test with V79 Chinese hamster cells, in vivo micronucleus assay in mouse, and mouse dominant lethal test.
Treatment of male rats with oral doses of ketotifen ³ 10 mg/kg/day orally [6,667 times the maximum recommended human ocular dose of 0.0015 mg/kg/day on a mg/kg basis (MRHOD)] for 70 days prior to mating resulted in mortality and a decrease in fertility. Treatment with ketotifen did not impair fertility in female rats receiving up to 50 mg/kg/day of ketotifen orally (33,333 times the MRHOD) for 15 days prior to mating.
Oral treatment of pregnant rabbits during organogenesis with 45 mg/kg/day of ketotifen (30,000 times the MRHOD) resulted in an increased incidence of retarded ossification of the sternebrae. However, no effects were observed in rabbits treated with up to 15 mg/kg/day (10,000 times the MRHOD). Similar treatment of rats during organogenesis with 100 mg/kg/day of ketotifen (66,667 times the MRHOD) did not reveal any biologically relevant effects.
Oral treatment of pregnant rats (up to 100 mg/kg/day or 66,667 times the MRHOD) and rabbits (up to 45 mg/kg/day or 30,000 times the MRHOD) during organogenesis did not result in any biologically relevant embryofetal toxicity. In the offspring of the rats that received ketotifen orally from day 15 of pregnancy to day 21 post partum at 50 mg/kg/day (33,333 times the MRHOD), a maternally toxic treatment protocol, the incidence of postnatal mortality was slightly increased, and body weight gain during the first four days post partum was slightly decreased.
Ketotifen fumarate has been identified in breast milk in rats following oral administration. It is not known whether topical ocular administration could result in sufficient systemic absorption to produce detectable quantities in breast milk. Nevertheless, caution should be exercised when ketotifen fumarate is administered to a nursing mother.
Safety and effectiveness in pediatric patients below the age of 3 years have not been established.
Any patient who experiences blurred vision or somnolence should not drive or operate machines.
In controlled clinical studies, conjunctival injection, headaches, and rhinitis were reported at an incidence of 10 to 25%. The occurrence of these side effects was generally mild. Some of these events were similar to the underlying ocular disease being studied.
The following ocular and non-ocular adverse reactions were reported at an incidence of less than 5%:
Ocular: Allergic reactions, burning or stinging, conjunctivitis, discharge, dry eyes, eye pain, eyelid disorder, itching, keratitis, lacrimation disorder, mydriasis, photophobia, and rash.
Non-Ocular: Flu syndrome, pharyngitis.
Oral ingestion of the contents of a 5 mL bottle would be equivalent to 1.725 mg of ketotifen fumarate. Clinical results have shown no serious signs or symptoms after the ingestion of up to 20 mg of ketotifen fumarate.
Pharmacotherapeutic group: Ophthalmologicals, other antiallergics
Ketotifen is a histamine H1-receptor antagonist. In vivo animal studies and in vitro studies suggest the additional activities of mast cell stabilisation and inhibition of infiltration, activation and degranulation of eosinophils.
In a pharmacokinetic study conducted in 18 healthy volunteers with Zaditen eye drops, plasma levels of ketotifen after repeated ocular administration for 14 days were in most cases below the limit of quantitation (20pg/ml).
After oral administration, ketotifen is eliminated biphasically with an initial half-life of 3 to 5 hours and a terminal half-life of 21 hours. About 1% of the substance is excreted unchanged in the urine within 48 hours and 60 to 70% as metabolites. The main metabolite is the practically inactive ketotifen-Nglucuronide.
Preclinical data reveal no special hazard which is considered relevant in connection with use of Zaditen eye drops in humans based on conventional studies of safety pharmacology, repeated dose toxicity, genotoxicity, carcinogenic potential and toxicity to reproduction.
Pillintrip.com does not provide medical or pharmacological advice, diagnosis or treatment.
Attention! Always consult to a doctor or pharmacist before using pills or medicines.
All rights reserved © Pillintrip.com 2016 - 2022

All

Select the section you want to search in

All
Consumer
Professional
Pill ID
Interactions
News
FDA Alerts
Approvals
Pipeline
Clinical Trials
Care Notes
Natural Products

Browse all medications:

a
b
c
d
e
f
g
h
i
j
k
l
m
n
o
p
q
r
s
t
u
v
w
x
y
z
0-9

Advanced Search

I accept the Terms and Privacy Policy

Select one or more newsletters to continue.

Ad Choices

We comply with the HONcode standard for trustworthy health information. Verify here

Copyright © 2000-2022 Drugs.com. All rights reserved.

Tofen may be available in the countries listed below.
Ketotifen fumarate (a derivative of Ketotifen) is reported as an ingredient of Tofen in the following countries:
Important Notice: The Drugs.com international database is in BETA release. This means it is still under development and may contain inaccuracies. It is not intended as a substitute for the expertise and judgement of your physician, pharmacist or other healthcare professional. It should not be construed to indicate that the use of any medication in any country is safe, appropriate or effective for you. Consult with your healthcare professional before taking any medication.
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
The easiest way to lookup drug information, identify pills, check interactions and set up your own personal medication records. Available for Android and iOS devices.
Subscribe to Drugs.com newsletters for the latest medication news, new drug approvals, alerts and updates.
Drugs.com provides accurate and independent information on more than 24,000 prescription drugs, over-the-counter medicines and natural products. This material is provided for educational purposes only and is not intended for medical advice, diagnosis or treatment. Data sources include IBM Watson Micromedex (updated 3 May 2022), Cerner Multum™ (updated 3 June 2022), ASHP (updated 16 May 2022) and others.
Help support Drugs.com by allowing ads...

This request was blocked by security rules.

Main Page

Discuss

All Pages

Community

Interactive Maps

Andor

Tales of the Jedi

Obi-Wan Kenobi

Knights of the Old Republic – Remake

The Bad Batch

The High Republic

The Clone Wars

Rogue One

Solo

A Droid Story

Rogue Squadron

The Mandalorian

The Book of Boba Fett

Obi-Wan Kenobi

Andor

Ahsoka

The Acolyte

Lando

Skeleton Crew

The Clone Wars

Rebels

Resistance

The Bad Batch

Visions

Tales of the Jedi

Young Jedi Adventures

Droids

Ewoks

Clone Wars

The Clone Wars

Audiobooks

Comics

Cookbooks

Game books

Magazines

Music books

Reference books

Short stories

Novels

Young readers

Featured articles

Good articles

Comprehensive articles

Culture

Events

Individuals

Locations

Organizations

Species

Technology

Behind the scenes

Attribution

Canon

Copyright

Layout Guide

Manual of Style

Dom Sub Aftercare
Call Girls In Illinois
Asian Escort Paris

Tofen

Report Page